China’s Sinopharm reports strong interim results for its Covid-19 vaccine

China’s Sinopharm reports strong interim results for its Covid-19 vaccine

A vaccine developed by China National Pharmaceutical Group (Sinopharm) has been found to be 79.34 per cent effective against Covid-19, according to an interim analysis, the company said.

The vaccine was shown to be safe, and participants receiving the two-dose course produced a high level of antibodies against the virus at a rate of 99.52 per cent, according to a statement posted on Wednesday by the company’s subsidiary Beijing Institute of Biological Products – which has also formally submitted an application to China’s regulators for conditional listing, it said.

Few further details were given – including critical information about the number of people evaluated to reach the results, or which data had been analysed.

The vaccine is in clinical trials in several countries, including the United Arab Emirates, Bahrain, Jordan, Peru and Argentina.